Tahikininski receptor 1

Agonisti

• GR-73632 - potentan i selektivan agonist, EC₅₀ 2nM, polipeptid sa pet aminokiselina

Antagonisti

• Aprepitant
• Kasopitant
• Ezlopitant
• Fosaprepitant
• Lanepitant
• Maropitant
• Vestipitant
• L-733,060
• L-741,671
• L-742,694
• RP-67580 - potentan i selektivan antagonist, Ki 2.9nM, (3aR,7aR)-oktahidro-2-[1-imino-2-(2-metoksifenil)etil ]-7,7-difenil-4H-izoindol
• RPR-100,893
• CP-96345
• CP-99994
• GR-205,171
• TAK-637
• T-2328

1. ^ Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE (1991). „Molecular cloning, structural characterization and functional expression of the human substance P receptor”. Biochem. Biophys. Res. Commun. 179 (3): 1232—40. PMID 1718267. doi:10.1016/0006-291X(91)91704-G. 
2. ^ ^{а б в} Ho, Z W.., Douglas S. D. (decembar 2004). „Substance P and neurokinin-1 receptor modulation of HIV”. Journal of Neuroimmunology. 157 (1—2): 48—55. PMID 15579279. doi:10.1016/j.jneuroim.2004.08.022. Архивирано из оригинала 1. 9. 2009. г. Приступљено 15. 4. 2011. 
3. ^ ^{а б} Page, M N.. (avgust 2005). „New challenges in the study of the mammalian Tachykinins”. Peptides. 26 (8): 1356—1368. PMID 16042976. doi:10.1016/j.peptides.2005.03.030. Архивирано из оригинала 1. 9. 2009. г. Приступљено 15. 4. 2011. 
4. ^ ^{а б} Datar P.; Srivastava S.; Coutinho E.; Govil G. (2004). „Substance P: Structure, Function, and Therapeutics”. Current Topics in Medicinal Chemistry. 4 (1): 75—103. PMID 14754378. doi:10.2174/1568026043451636. Архивирано из оригинала 18. 9. 2009. г. Приступљено 15. 4. 2011. 
5. ^ ^{а б} Satake H., Kawada T. (avgust 2006). „Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors”. Current Drug Targets. 7 (8): 963—974. doi:10.2174/138945006778019273. Архивирано из оригинала 3. 9. 2009. г. Приступљено 15. 4. 2011. 
6. ^ ^{а б} Almeida, A T.., Rojo J., Nieto P. M., Hernandez M., Martin J. D., Candenas M. L. (avgust 2004). „Tachykinins and Tachykinins Receptors: Structure and Activity Relationships”. Current Medicinal Chemistry. 11 (15): 2045—2081. PMID 15279567. Архивирано из оригинала 1. 9. 2009. г. Приступљено 15. 4. 2011. 
7. ^ Humphrey, JM (2003). „Medicinal chemistry of selective neurokinin-1 antagonists”. Current topics in medicinal chemistry. 3 (12): 1423—35. PMID 12871173. doi:10.2174/1568026033451925. 
8. ^ Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M (2009). „Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 29 (1): 222—33. PMC 2775560 . PMID 19129399. doi:10.1523/JNEUROSCI.4315-08.2009. 
9. ^ Perlis RH, Purcell S, Fagerness J, Kirby A, Petryshen TL, Fan J, Sklar P (2008). „Family-based association study of lithium-related and other candidate genes in bipolar disorder”. Arch. Gen. Psychiatry. 65 (1): 53—61. PMID 18180429. doi:10.1001/archgenpsychiatry.2007.15. 
10. ^ George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M (2008). „Neurokinin 1 receptor antagonism as a possible therapy for alcoholism”. Science (journal). 319 (5869): 1536—9. PMID 18276852. doi:10.1126/science.1153813. 
11. ^ Jordan, K (2006). „Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy”. Onkologie. 29 (1-2): 39—43. PMID 16514255. doi:10.1159/000089800. 

• Burcher, E (1989). „The study of tachykinin receptors.”. Clin. Exp. Pharmacol. Physiol. 16 (6): 539—43. PMID 2548782. doi:10.1111/j.1440-1681.1989.tb01602.x. 
• NW, Kowall; Quigley BJ; JE, Krause; et al. (1993). „Substance P and substance P receptor histochemistry in human neurodegenerative diseases.”. Regul. Pept. 46 (1-2): 174—85. PMID 7692486. doi:10.1016/0167-0115(93)90028-7. 
• Patacchini R, Maggi CA (2002). „Peripheral tachykinin receptors as targets for new drugs.”. Eur. J. Pharmacol. 429 (1-3): 13—21. PMID 11698023. doi:10.1016/S0014-2999(01)01301-2. 
• Saito R, Takano Y, Kamiya HO (2003). „Roles of substance P and NK(1) receptor in the brainstem in the development of emesis.”. J. Pharmacol. Sci. 91 (2): 87—94. PMID 12686752. doi:10.1254/jphs.91.87. 
• Fong TM, Yu H, Huang RR, Strader CD (1992). „The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides.”. Biochemistry. 31 (47): 11806—11. PMID 1280161. doi:10.1021/bi00162a019. 
• Fong TM, Huang RR, Strader CD (1993). „Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor.”. J. Biol. Chem. 267 (36): 25664—7. PMID 1281469. 
• TM, Fong; Anderson SA; H, Yu; et al. (1992). „Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor.”. Mol. Pharmacol. 41 (1): 24—30. PMID 1310144. 
• Takahashi K, Tanaka A, Hara M, Nakanishi S (1992). „The primary structure and gene organization of human substance P and neuromedin K receptors.”. Eur. J. Biochem. 204 (3): 1025—33. PMID 1312928. doi:10.1111/j.1432-1033.1992.tb16724.x. 
• DA, Walsh; Mapp PI; J, Wharton; et al. (1992). „Localisation and characterisation of substance P binding to human synovial tissue in rheumatoid arthritis.”. Ann. Rheum. Dis. 51 (3): 313—7. PMC 1004650 . PMID 1374227. doi:10.1136/ard.51.3.313. 
• NP, Gerard; Garraway LA; RL, Eddy; et al. (1991). „Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones.”. Biochemistry. 30 (44): 10640—6. PMID 1657150. doi:10.1021/bi00108a006. 
• B, Hopkins; Powell SJ; P, Danks; et al. (1991). „Isolation and characterisation of the human lung NK-1 receptor cDNA.”. Biochem. Biophys. Res. Commun. 180 (2): 1110—7. PMID 1659396. doi:10.1016/S0006-291X(05)81181-7. 
• Y, Takeda; Chou KB; J, Takeda; et al. (1991). „Molecular cloning, structural characterization and functional expression of the human substance P receptor.”. Biochem. Biophys. Res. Commun. 179 (3): 1232—40. PMID 1718267. doi:10.1016/0006-291X(91)91704-G. 
• S, Giuliani; Barbanti G; D, Turini; et al. (1992). „NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype.”. Eur. J. Pharmacol. 203 (3): 365—70. PMID 1723045. doi:10.1016/0014-2999(91)90892-T. 
• H, Ichinose; Katoh S; T, Sueoka; et al. (1991). „Cloning and sequencing of cDNA encoding human sepiapterin reductase--an enzyme involved in tetrahydrobiopterin biosynthesis.”. Biochem. Biophys. Res. Commun. 179 (1): 183—9. PMID 1883349. doi:10.1016/0006-291X(91)91352-D. 
• Thöny B, Heizmann CW, Mattei MG (1995). „Human GTP-cyclohydrolase I gene and sepiapterin reductase gene map to region 14q21-q22 and 2p14-p12, respectively, by in situ hybridization.”. Genomics. 26 (1): 168—70. PMID 7782081. doi:10.1016/0888-7543(95)80101-Q. 
• TM, Fong; Cascieri MA; H, Yu; et al. (1993). „Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345.”. Nature. 362 (6418): 350—3. PMID 8384323. doi:10.1038/362350a0. 
• JM, Derocq; Ségui M; C, Blazy; et al. (1997). „Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists.”. FEBS Lett. 399 (3): 321—5. PMID 8985172. doi:10.1016/S0014-5793(96)01346-4. 
• De Felipe C; JF, Herrero; O'Brien JA; et al. (1998). „Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.”. Nature. 392 (6674): 394—7. PMID 9537323. doi:10.1038/32904.